|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2007-2-5
|
|
pubmed:abstractText |
The long QT syndrome is a rare disease. The prevalence is estimated at 1/5 000 to 1/20,000. Numerous drugs are contra-indicated because they can lengthen the QT interval. A case of pollen allergy in an adolescent with LQTS is described. The possibility to prescribe anti-H1 drugs is reviewed since cases of torsades de pointe and even deaths have been reported for terfenadine and astemizole. Diphenhydramine, orphenadrine and hydroxyzine are contra-indicated. No accidents and no effects on the QT interval have been published for ebastine, fexofenadine, desloratadine and levocetirizine. These anti-H1 drugs could be used with great care, without any association with drugs resulting in low serum potassium level. Azelastine eye drops have been authorized and a routine protection by inhaled corticosteroids during the pollinic period has been advised in this adolescent treated by betablockers.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adrenergic beta-Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Asthmatic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Butyrophenones,
http://linkedlifedata.com/resource/pubmed/chemical/Cetirizine,
http://linkedlifedata.com/resource/pubmed/chemical/Cromolyn Sodium,
http://linkedlifedata.com/resource/pubmed/chemical/Histamine H1 Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Piperazines,
http://linkedlifedata.com/resource/pubmed/chemical/Piperidines,
http://linkedlifedata.com/resource/pubmed/chemical/Terfenadine,
http://linkedlifedata.com/resource/pubmed/chemical/ebastine,
http://linkedlifedata.com/resource/pubmed/chemical/fexofenadine,
http://linkedlifedata.com/resource/pubmed/chemical/levocetirizine
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1764-1489
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
38
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
347-50
|
|
pubmed:dateRevised |
2008-2-26
|
|
pubmed:meshHeading |
pubmed-meshheading:17274518-Adolescent,
pubmed-meshheading:17274518-Adrenergic beta-Antagonists,
pubmed-meshheading:17274518-Anti-Asthmatic Agents,
pubmed-meshheading:17274518-Butyrophenones,
pubmed-meshheading:17274518-Cetirizine,
pubmed-meshheading:17274518-Conjunctivitis, Allergic,
pubmed-meshheading:17274518-Cromolyn Sodium,
pubmed-meshheading:17274518-Diabetes Mellitus, Type 1,
pubmed-meshheading:17274518-Heart,
pubmed-meshheading:17274518-Histamine H1 Antagonists,
pubmed-meshheading:17274518-Humans,
pubmed-meshheading:17274518-Long QT Syndrome,
pubmed-meshheading:17274518-Male,
pubmed-meshheading:17274518-Piperazines,
pubmed-meshheading:17274518-Piperidines,
pubmed-meshheading:17274518-Rhinitis, Allergic, Seasonal,
pubmed-meshheading:17274518-Terfenadine
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Long QT syndrome in a patient with allergic rhinoconjunctivitis and auto-immune diabetes: focus on the choice of anti-H1 drugs.
|
|
pubmed:affiliation |
Department of Internal Medicine - Clinical Immunology and Allergology, University Hospital, 29 avenue du Maréchal de Lattre de Tassigny, 54035 Nancy Cedex, France.
|
|
pubmed:publicationType |
Journal Article,
Case Reports
|
